Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 90 versus RENO 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 90 versus RENO 30.
HYPAQUE-M,90% vs RENO-30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
Adults: 30 mL (30 g iodine) intravenously as a single dose for imaging procedures; may repeat once if needed.
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
Terminal half-life: 1-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: >95% unchanged; biliary/fecal: <5%
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent